MSLE Company Profile and Key Details

currently trading near 52-week highs band. Valuation shows Satellos Bioscience Inc. Common Stock trading at a premium to the broader market with a P/E of -3.72. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.25, suggesting 189.15% upside. Our AI forecast model points to short-term weakness (-0.89% over two weeks), a medium-term fall (-55.34% over three months), and a longer-term loss (-99.82% over one year), with expected trading ranges indicating moderate volatility.

Satellos Bioscience Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $8.06. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Satellos Bioscience Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.89%, with price expected at $5.57 by June 19, 2026, within a range of $5.09 to $6.12 3-Month Outlook: Projected fall of -55.34%, reaching $2.51 by September 03, 2026, with a range of $2.41 to $2.60. 1-Year Outlook: Projected loss of -99.82%, with price at $0.01 by June 04, 2027, within a range of $0.00 to $0.11.

Satellos Bioscience Inc. Common Stock (NASDAQ:MSLE) closed at $5.62 USD, losing -$0.39 (-6.49%) from the previous close of $6.01. The stock is currently mid-range between its 52-week high and low $4.52 and $13.39. With a market capitalization of about $7.24 million, Satellos Bioscience Inc. Common Stock is classified as a micro-cap and shows market-like volatility (beta ~1.17). Key stats such as the average daily volume over the past year has been around 73.19 thousand shares, volume is running light vs its 52-week average. Headquartered in Toronto, ON, Satellos Bioscience Inc. Common Stock operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Francis Gleeson, the company employs approximately 14 people and listed since May 10, 2024. Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics.

Satellos Bioscience Inc. Common Stock trades at a P/E ratio of -3.72, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.5 suggesting the stock is closer to book value. The P/FCF stands at -0.29, also above market averages.